The firm said in May it was considering the surcharge following disclosure of a $40 million tariff-related headwind for 2025.

Adding the firm's multi-cancer early detection test to standard-of-care screening demonstrated substantially greater additional cancer detection than in Pathfinder.

The shares are expected to begin trading on June 18 under the ticker symbol CAI, and the offering is expected to close on June 20.

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said Monday that the investment from ...

NEW YORK — EDX Medical Group said on Monday that it has a signed a memorandum of understanding with UK-based healthcare group Spire Healthcare around diagnostic products and testing services. Spire ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.